{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:31:29Z","timestamp":1787725889338,"version":"build-2784847793"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Major depressive disorder (MDD) in late life is associated with an increased risk of Alzheimer's disease (AD), but the molecular basis for this depressiondementia continuum remains poorly understood. \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) processes both beneficial substrates (e.g., neuregulin-1 for synaptic plasticity) and pathological substrates (e.g., amyloid precursor protein for A\u03b2 generation), making it a candidate molecular bridge. We hypothesized that plasma BACE1 levels would exhibit distinct age-dependent alteration patterns in MDD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a retrospective single-blind design, we enrolled 52 older (65\u201380 years) and 55 younger (30\u201340 years) MDD patients, with 75 age-matched healthy controls from the Beijing Biobank of Clinical Resources\u2013Mental Disorders. Plasma BACE1 protein was measured by ELISA and enzymatic activity via FRET using an APP Swedish mutation substrate. Depression severity was assessed using HAMD; cognitive function using WCST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Plasma BACE1 protein levels were significantly lower in MDD patients than in HCs (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.029). A two-way ANOVA revealed a significant Age \u00d7 Diagnosis interaction (\n                      <jats:italic>F<\/jats:italic>\n                      (1, 178) = 19.264,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), formally supporting the biphasic pattern: young MDD patients showed a ~41% reduction (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), while older MDD patients showed a numerical increase (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.051). BACE1 enzymatic activity did not differ among groups, and no protein\u2013activity correlation was observed within any subgroup, indicating a \"decoupling\" between protein expression and catalytic function. Plasma BACE1 protein levels in older MDD patients negatively correlated with executive dysfunction (WCST failure-to-maintain-set;\n                      <jats:italic>r<\/jats:italic>\n                      = \u22120.281,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.044), while BACE1 activity in young MDD patients negatively correlated with age (\n                      <jats:italic>r<\/jats:italic>\n                      = \u22120.276,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.042). A significant Age \u00d7 Sex interaction (\n                      <jats:italic>F<\/jats:italic>\n                      (1, 178) = 6.756, P = 0.010) revealed an agedependent sexual dimorphism: young male controls had higher BACE1 levels than young female controls (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.010), a pattern that reversed direction in older controls and was attenuated in both MDD subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings reveal a substrate-selective, age-dependent, and sexinformed biphasic alteration of plasma BACE1 in MDD, supporting a unifying framework in which the same enzyme is associated with depressive pathology in young patients (via loss of beneficial substrate processing) and neurodegenerative transition in older patients (via pathological substrate cleavage), with the depression-dementia continuum as the mechanistic bridge.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1917834","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:04:04Z","timestamp":1787724244000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Age-dependent biphasic alterations and protein-activity decoupling of plasma BACE1 in major depressive disorder"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiang","family":"Gao","sequence":"first","affiliation":[{"name":"Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital","place":["Taiyuan, China"]},{"name":"Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Shanxi Provincial Innovation Center for Complex Formulation Technology of Anti-Tumor Drugs","place":["Changzhi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[{"name":"Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoli","family":"Sun","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Chen","sequence":"additional","affiliation":[{"name":"Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.5.530","article-title":"Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis","volume":"63","author":"Ownby","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-021-02313-0","article-title":"Could alpha-Klotho unlock the key between depression and dementia in the elderly: from animal to human studies","volume":"58","author":"Gao","year":"2021","journal-title":"Mol Neurobiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The beta-Secretase BACE1 in Alzheimer's disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2217\/pme-2016-0033","article-title":"BACE1 levels are increased in plasma of Alzheimer's disease patients compared with matched cognitively healthy controls","volume":"13","author":"Manzine","year":"2016","journal-title":"Per Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.3372-12.2013","article-title":"Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling","volume":"33","author":"Fleck","year":"2013","journal-title":"J Neurosci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13430","article-title":"BACE1: More than just a beta-secretase","volume":"23","author":"Taylor","year":"2022","journal-title":"Obes Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812840","article-title":"Randomized trial of Verubecestat for prodromal Alzheimer's disease","volume":"380","author":"Egan","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of Lanabecestat for treatment of early and mild Alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2392","article-title":"Neuregulin 1 in neural development, synaptic plasticity and schizophrenia","volume":"9","author":"Mei","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-019-00127-6","article-title":"Serum beta-secretase 1 (BACE1) activity as candidate biomarker for late-onset Alzheimer's disease","volume":"42","author":"Cervellati","year":"2020","journal-title":"Geroscience"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3233\/jad-160227","article-title":"The cerebrospinal fluid neurogranin\/BACE1 ratio is a potential correlate of cognitive decline in Alzheimer's disease","volume":"53","author":"De Vos","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000489847","article-title":"Neurogranin and BACE1 in CSF as potential biomarkers differentiating depression with cognitive deficits from early Alzheimer's disease: A pilot study","volume":"8","author":"Schipke","year":"2018","journal-title":"Dement Geriatr Cognit Dis Extra"},{"key":"B13","doi-asserted-by":"publisher","first-page":"20375","DOI":"10.1038\/s41598-021-99794-9","article-title":"Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression","volume":"11","author":"Siafarikas","year":"2021","journal-title":"Sci Rep"},{"key":"B14","article-title":"Computerized Wisconsin Card Sorting Test: comparison with manual administration","volume":"12","author":"Tien","year":"1996","journal-title":"Kaohsiung J Med Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/s0920-9964(03)00174-9","article-title":"Effect of orthography on the verbal fluency performance in schizophrenia: examination using Japanese patients","volume":"69","author":"Sumiyoshi","year":"2004","journal-title":"Schizophr Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.682691","article-title":"Reduced plasma levels of alpha-Klotho and their correlation with Klotho polymorphisms in elderly patients with major depressive disorders","volume":"12","author":"Gao","year":"2021","journal-title":"Front Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2012.173","article-title":"Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons","volume":"31","author":"Kuhn","year":"2012","journal-title":"EMBO J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nn1797","article-title":"Bace1 modulates myelination in the central and peripheral nervous system","volume":"9","author":"Hu","year":"2006","journal-title":"Nat Neurosci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1132341","article-title":"Control of peripheral nerve myelination by the beta-secretase BACE1","volume":"314","author":"Willem","year":"2006","journal-title":"Sci (New York NY)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m112.415505","article-title":"Beta-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects","volume":"287","author":"Hitt","year":"2012","journal-title":"J Biol Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251317730","article-title":"Identification of the enzymatic cleavage relationship between anti-aging protein alpha-Klotho and Alzheimer's disease biomarker BACE1","volume":"104","author":"Gao","year":"2025","journal-title":"J Alzheimers Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710373105","article-title":"Alteration of BACE1-dependent NRG1\/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice","volume":"105","author":"Savonenko","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2025.103890","article-title":"Abnormal myelin could be a mediator of childhood-trauma-induced depression: A quantitative synthetic MRI study","volume":"48","author":"Wen","year":"2025","journal-title":"NeuroImage Clin"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2017.02.007","article-title":"Increased plasma beta-secretase 1 may predict conversion to Alzheimer's disease dementia in individuals with mild cognitive impairment","volume":"83","author":"Shen","year":"2018","journal-title":"Biol Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m004175200","article-title":"Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase","volume":"275","author":"Huse","year":"2000","journal-title":"J Biol Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m003202200","article-title":"Maturation and pro-peptide cleavage of beta-secretase","volume":"275","author":"Capell","year":"2000","journal-title":"J Biol Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m009361200","article-title":"Characterization of the glycosylation profiles of Alzheimer's beta-secretase protein Asp-2 expressed in a variety of cell lines","volume":"276","author":"Charlwood","year":"2001","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-012-8377-3","article-title":"Brain endogenous estrogen levels determine responses to estrogen replacement therapy via regulation of BACE1 and NEP in female Alzheimer's transgenic mice","volume":"47","author":"Li","year":"2013","journal-title":"Mol Neurobiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.mce.2013.12.018","article-title":"Brain sex matters: estrogen in cognition and Alzheimer's disease","volume":"389","author":"Li","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.0864-20.2021","article-title":"Sex-specific regulation of beta-secretase: A novel estrogen response element (ERE)-dependent mechanism in Alzheimer's disease","volume":"42","author":"Cui","year":"2022","journal-title":"J Neurosci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.1180-10.2010","article-title":"Genetic targeting aromatase in male amyloid precursor protein transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment","volume":"30","author":"McAllister","year":"2010","journal-title":"J\u00a0Neurosci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.07.001","article-title":"Brain Abeta load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD","volume":"15","author":"Vergallo","year":"2019","journal-title":"Alzheimers Dement"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1917834\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:04:05Z","timestamp":1787724245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1917834\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":32,"alternative-id":["10.3389\/fpsyt.2026.1917834"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1917834","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1917834"}}